SCHEMBL3673953

SCHEMBL3673953

COC(=O)c1ccc(C=Cc2ccc(O)c(O)c2CC=C(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 5/20 0.53
OPRD1 P41143 1/20 0.47
DHODH Q02127 1/20 0.45
CYP19A1 P11511 6/20 0.44
ALOX5 P09917 4/20 0.44
PTGS2 P35354 3/20 0.44
MAOB P27338 2/20 0.44
MAOA P21397 1/20 0.44
PDPK1 O15530 1/20 0.43
TTR P02766 1/20 0.43
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 1/20 0.41
ABCB1 P08183 3/20 0.40
TYR P14679 1/20 0.40
APP P05067 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3673951 1.00 PTPN1 (0.53) PTPN1OPRD1DHODHCYP19A1ALOX5
SCHEMBL3673040 0.83 MAOA (0.66) PTPN1CYP19A1ALOX5PTGS2MAOB
SCHEMBL3673043 0.83 MAOA (0.66) PTPN1CYP19A1ALOX5PTGS2MAOB
SCHEMBL3670315 0.82 PTPN1 (0.52) PTPN1CYP19A1ALOX5PTGS2MAOB
SCHEMBL3670316 0.82 PTPN1 (0.52) PTPN1CYP19A1ALOX5PTGS2MAOB
SCHEMBL3675131 0.80 PTPN1 (0.58) PTPN1CYP19A1ALOX5PTGS2MAOB
SCHEMBL3675133 0.80 PTPN1 (0.58) PTPN1CYP19A1ALOX5PTGS2MAOB
SCHEMBL4259780 0.78 BACE1 (0.40) PTPN1CYP19A1ALOX5PTGS2MAOB
SCHEMBL4259776 0.78 BACE1 (0.40) PTPN1CYP19A1ALOX5PTGS2MAOB
SCHEMBL3674334 0.77 PTGS2 (0.50) PTPN1OPRD1DHODHCYP19A1ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4425628-B2 2010-03-03 JP claimed
US-20060106014-A1 Methods for treating diabetes ELI LILLY AND COMPANY 2006-05-18 US claimed
WO-2006044556-A2 DUAL INHIBITORS OF LIPOXYGENASE FOR TREATING DIABETES GALILEO PHARMACEUTICALS, INC. (US) 2006-04-27 WO claimed
EP-1435894-A4 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO PHARMACEUTICALS INC (US) 2005-07-06 EP claimed
JP-2005505519-A 2005-02-24 JP claimed
EP-1435894-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS Galileo Pharmaceuticals, Inc. (US) 2004-07-14 EP claimed
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2003-04-17 US claimed
WO-2003009807-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO LABORATORIES, INC. (US) 2003-02-06 WO claimed
US-7629375-B2 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2009-12-08 US disclosed
US-20060178356-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods GALILEO PHARMACEUTICALS, INC. 2006-08-10 US disclosed
US-20060106014-A1 Methods for treating diabetes ELI LILLY AND COMPANY 2006-05-18 US disclosed
WO-2006044556-A2 DUAL INHIBITORS OF LIPOXYGENASE FOR TREATING DIABETES GALILEO PHARMACEUTICALS, INC. (US) 2006-04-27 WO disclosed
EP-1435894-A4 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO PHARMACEUTICALS INC (US) 2005-07-06 EP disclosed
US-20050142155-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER INC. 2005-06-30 US disclosed
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods GALILEO PHARMACEUTICALS, INC. 2005-05-26 US disclosed
EP-1435894-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS Galileo Pharmaceuticals, Inc. (US) 2004-07-14 EP disclosed
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2003-04-17 US disclosed
WO-2003009807-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO LABORATORIES, INC. (US) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106014-A1 Methods for treating diabetes ALOX5, ALOX15, ALOX15B PTPN1 2549/4885OPRD1 1653/4885DHODH 237/4885
US-20050142155-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 PTPN1 4044/4885OPRD1 4151/4885DHODH 1250/4885
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 PTPN1 4044/4885OPRD1 4151/4885DHODH 1250/4885
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 PTPN1 4044/4885OPRD1 4151/4885DHODH 1250/4885
US-20060178356-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 PTPN1 4044/4885OPRD1 4151/4885DHODH 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.